Abstract:Diabetes mellitus is a chronic metabolic disorder marked by hyperglycemia and systemic complications, including hepatic dysfunction, significantly contributing to disease progression and morbidity. This article reviews recent advances in gene-based therapeutic strategies targeting hepatic complications in diabetes, offering a promising approach for precision medicine by addressing underlying molecular mechanisms. Traditional treatments for hepatic complications in diabetes often manage symptoms rather than molecular causes, showing limited efficacy. Gene-based therapies are poised to correct dysfunctional pathways and restore hepatic function. Fundamental gene therapy approaches include gene silencing via small interfering RNAs (siRNAs) to target hepatic glucose production, lipid metabolism, and inflammation. Viral vectors can restore insulin sensitivity and reduce oxidative stress in diabetic livers. Genome editing, especially CRISPR-Cas9, allows the precise modification of disease-associated genes, offering immense potential for hepatic complication treatment. Strategies using CRISPR-Cas9 to enhance insulin receptor expression and modulate aberrant lipid regulatory genes are explored. Safety challenges in gene-based therapies, such as off-target effects and immune responses, are discussed. Advances in nanoparticle-based delivery systems and targeted gene editing techniques offer solutions to enhance specificity and minimize adverse effects. In conclusion, gene-based therapeutic approaches are a transformative direction in managing hepatic complications in diabetes. Further research is needed to optimize efficacy, safety, and long-term outcomes. Nevertheless, these innovative strategies promise to improve the lives of individuals with diabetes by addressing hepatic dysfunction's genetic root causes.

Liver gene transfer for metabolite detoxification in inherited metabolic diseases

Liver‐directed gene therapy for inherited metabolic diseases

Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders

Drug-induced liver injury related to gene therapy: A new challenge to be managed

Therapeutic liver cell transplantation to treat a genetic liver defect

In vivo liver targeted genome editing as therapeutic approach: progresses and challenges

Gene editing technology as an approach to the treatment of liver diseases

Novel Therapeutic Modalities For Hepatic Diseases

Exploiting the unique regenerative capacity of the liver to underpin cell and gene therapy strategies for genetic and acquired liver disease

Messenger RNA therapy for rare genetic metabolic diseases

Advancing Liver Gene Therapy: Enhanced Transduction with GalNAc-Bioconjugated rAAV Capsids

Therapeutic liver cell transplantation to treat murine PKU

Gene Editing Correction of a Urea Cycle Defect in Organoid Stem Cell Derived Hepatocyte-like Cells

Mitochondrial Dysfunction: A Promising Therapeutic Target for Liver Diseases

Novel gene-based therapeutic approaches for the management of hepatic complications in diabetes: Reviewing recent advances

In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges

Organoid-guided Precision Hepatology for Metabolic Liver Disease

Focus on Diagnosis and Treatment of Genetic Liver Disorders

Gene therapy for neurotransmitter‐related disorders

GENE THERAPY PREVENTS HEPATIC MITOCHONDRIAL DYSFUNCTION IN MURINE DEOXYGUANOSINE KINASE DEFICIENCY

Nanogene editing drug delivery systems in the treatment of liver fibrosis